$FMKT: How Deregulation Is Powering Digital Healthcare Through Hims & Hers Health
Imagine solving a personal health issue without ever stepping into a doctor’s office. Not long ago, that would have sounded unrealistic—maybe even illegal. Today it’s normal, and one big reason is something that doesn’t often make headlines: deregulation. In the case of Hims & Hers Health, Inc., loosening telehealth rules transformed a niche startup into a national platform. It’s also why the Free Markets ETF (FMKT)—a fund designed to benefit from deregulation that I launched in June with 3 other partners—holds Hims & Hers in its portfolio.
Hims & Hers makes awkward doctor visits unnecessary. The company runs a telehealth platform connecting patients with licensed providers for hair loss, mental health, sexual wellness, and primary care. It has even expanded into weight-loss treatments, providing access to popular medications through online consultations. Patients interact through an app or website, receive prescriptions, and get medications delivered directly. It’s healthcare delivered like e-commerce—and consumers have embraced it.
None of this would exist without policy change. Telemedicine once faced heavy restrictions: doctors couldn’t treat new patients without in-person exams, and certain prescriptions were banned online. The COVID-19 pandemic changed that. Emergency rules in 2020 allowed remote visits and electronic prescribing . Those temporary changes are now largely permanent. The Drug Enforcement Administration (DEA) recently extended telehealth flexibilities that let providers prescribe controlled medications without in-person visits through at least 2025 . This means patients using Hims & Hers for anxiety, ADHD, or similar conditions can keep receiving care virtually. Deregulation, in this case, directly expanded both access and market opportunity.
The shift goes beyond healthcare. In 2024, the U.S. Supreme Court overturned the “Chevron doctrine,” which had long given regulators broad interpretive power. The decision limited agency authority, a move described by analysts as “a massive win for companies dealing with big regulatory burdens”. Around the same time, policymakers prioritized scaling back rules across industries. The Free Markets ETF was launched in mid-2025 to invest in companies poised to benefit from that trend. \
Healthcare has long been tangled in red tape, which is why FMKT’s inclusion of Hims & Hers makes sense. Regulation costs American businesses roughly $2.1 trillion annually and rolling it back often improves efficiency and innovation[^2]. Telehealth shows that effect clearly. By removing barriers to virtual care, regulators gave companies like Hims & Hers a green light to scale nationwide. States have since updated their laws to formally allow online doctor-patient relationships and asynchronous care (via messaging or questionnaires). Public support is strong: about 67 percent of Americans favor expanding access to asynchronous telehealth, with bipartisan backing.
That policy support has fueled rapid growth. In the second quarter of 2025, Hims & Hers’ revenue rose 73 percent year-over-year to $545 million, while net profit grew to $42.5 million. The company now serves more than 2.4 million subscribers, a 31 percent increase from the prior year. Fewer regulatory hurdles and nationwide reach helped accelerate that expansion.
Another advantage lies in the company’s structure. Hims & Hers acts as a platform linking patients, clinicians, and pharmacies—not as a medical provider or drugmaker. Because of this, it is not subject to the FDA’s prescription-drug marketing rules . That allows more flexibility in direct-to-consumer advertising for lifestyle medications such as ED pills or antidepressants . The company’s marketing, sleek and digital-first, reaches customers faster and with fewer compliance costs. It’s another form of deregulation in practice—the absence of traditional constraints that larger healthcare firms still face.
Still, investors must recognize the risks. The same deregulation that boosted Hims & Hers could reverse if authorities tighten oversight. Some experts worry about overprescription or inconsistent care when consultations occur entirely online. Hims & Hers uses board-certified clinicians and strict protocols, but any controversy in telehealth prescribing could invite scrutiny. FMKT investors, by extension, are betting that policymakers will continue to favor innovation over restriction.
Competition is another challenge. Amazon entered telehealth in 2024, offering online clinic visits and free prescription delivery for Prime members The announcement caused Hims & Hers shares to drop 15 percent that day . Analysts called Amazon’s entry a “serious competitive threat” due to its pricing power and reach. To stay competitive, Hims & Hers emphasizes personalized care—custom-compounded prescriptions and tailored programs that big platforms can’t easily replicate.
The company is also moving into new areas such as at-home lab testing and longevity programs to deepen customer relationships and diversify revenue[^3]. These services reinforce Hims & Hers’ positioning as a long-term health partner rather than a transactional telemedicine provider. It’s an effort to build loyalty in an increasingly competitive space.
For investors, Hims & Hers offers a textbook example of how deregulation can alter an industry’s trajectory. Policy shifts can unlock growth that technology alone cannot. In this case, a few key regulatory relaxations transformed healthcare access, allowed scalable digital infrastructure, and enabled profitability. FMKT was built to capture precisely these kinds of stories—where less bureaucracy leads to more innovation. The fund’s holdings span multiple sectors, but its philosophy is consistent: companies thrive when free-market conditions allow them to operate with fewer barriers.
The broader takeaway for investors is straightforward. Hims & Hers’ inclusion in FMKT signals confidence that deregulation will continue to favor companies blending technology and healthcare access. If the current deregulatory climate persists, this business stands to grow alongside it. Its addressable market—wellness, primary care, mental health, and now weight management—is expanding rapidly. At the same time, its digital infrastructure keeps costs low and scalability high.
Of course, no one should assume perpetual policy tailwinds. Political cycles shift, and healthcare oversight tends to tighten after growth spurts. Yet deregulation, once it gains public approval, can be difficult to reverse. Consumers who’ve tasted convenience rarely accept going back to the old system. That reality gives Hims & Hers a lasting advantage even if some rules are later reimposed.
In the end, deregulation may sound like an abstract policy idea, but its impact is tangible. It’s visible in the millions of Americans who now manage their health from home, and in companies like Hims & Hers that built a thriving business by serving that demand. The Free Markets ETF invests in exactly these types of outcomes—where market freedom drives efficiency and innovation.
For investors who believe that easing regulation unlocks growth across sectors, Hims & Hers Health offers a timely example. Its story isn’t about politics or headlines. It’s about how removing friction can let entrepreneurs reimagine industries. Deregulation, in this sense, is less about cutting rules and more about creating room for progress. FMKT’s bet on Hims & Hers is, at its core, a bet on that simple idea: when the rules of the game change to favor competition and consumer choice, value creation tends to follow.
Footnotes
Suzanne McGee, “US firms launch ETF to capitalize on Trump’s deregulation push,” Reuters, June 10, 2025 .
Sykon Asset Management, “About FMKT – Free Markets ETF,” FreeMarketsETF.com, accessed October 4, 2025 .
Heather Landi, “Hims & Hers stock falls 12% on revenue miss as company plots expansion into lab testing, longevity,” FierceHealthcare, August 4, 2025 .
“The State of Telehealth Access in 2023,” Hims & Hers Health (Medium blog), April 26, 2023 .
U.S. Drug Enforcement Administration, “DEA and HHS Extend Telemedicine Flexibilities through 2025,” November 15, 2024 .
Teresa Carr, “Amid Regulatory Gaps, Telehealth Prescribers Flourish,” Undark, November 1, 2023 .
Heather Landi, FierceHealthcare, August 4, 2025 .
“The State of Telehealth Access in 2023,” Hims & Hers Health (Medium blog), April 26, 2023 .
“Amazon’s push into telehealth knocks shares of Hims & Hers,” Reuters, November 14, 2024 .
“Amazon’s push into telehealth knocks shares of Hims & Hers,” Reuters, November 14, 2024 .
Past performance is no guarantee of future results.
The Fund’s investment objectives, risks, charges, expenses and other information are described in the statutory or summary prospectus, which must be read and considered carefully before investing. You may download the statutory or summary prospectus or obtain a hard copy by calling 855-994-4004 or visiting www.freemarketsetf.com. Please read the Prospectuses carefully before you invest.
Investing involves risk including the possible loss of principal.
FMKT is distributed by Foreside Fund Services, LLC.
Find full holding details and learn more about FMKT at
http://www.freemarketsetf.com.
Holdings are subject to change.
Deregulation Strategy Risks.The Fund’s strategy of investing in companies that may benefit from deregulatory measures entails significant risks, including those stemming from the unpredictable nature of regulatory trends. Deregulation is influenced by political, economic, and social factors, which can shift rapidly and in unforeseen directions. Changes in government priorities, political leadership, or public sentiment may result in the reversal of existing deregulatory policies or the introduction of new regulations that could adversely affect certain industries or companies. Further, while the Fund invests in companies expected to benefit from deregulatory initiatives, not all of these companies may achieve the expected advantages, whether fully, partially, or at all. The actual impact of deregulatory measures may vary widely depending on a company’s specific operational, financial, and competitive circumstances. Companies may also face challenges adapting to new regulatory environments, or their competitive positioning may be undermined by other market factors unrelated to deregulation. These risks could negatively affect the performance of the Fund’s portfolio.
Underlying Digital Assets ETP Risks. The Fund’s investment strategy, involving indirect exposure to Bitcoin, Ether, or any other Digital Assets through one or more Underlying ETPs, is subject to the risks associated with these Digital Assets and their markets. These risks include market volatility, regulatory changes, technological uncertainties, and potential financial losses. As with all investments, there is no assurance of profit, and investors should be cognizant of these specific risks associated with digital asset markets.
● Underlying Bitcoin and Ether ETP Risks: Investing in an Underlying ETP that focuses on Bitcoin, Ether, and/or other Digital Assets, either through direct holdings or indirectly via derivatives like futures contracts, carries significant risks. These include high market volatility influenced by technological advancements, regulatory changes, and broader economic factors. For derivatives, liquidity risks and counterparty risks are substantial. Managing futures contracts tied to either asset may affect an Underlying ETP’s performance. Each Underlying ETP, and consequently the Fund, depends on blockchain technologies that present unique technological and cybersecurity risks, along with custodial challenges in securely storing digital assets. The evolving regulatory landscape further complicates compliance and valuation efforts. Additionally, risks related to market concentration, network issues, and operational complexities in managing Digital Assets can lead to losses. For Ether specifically, risks associated with its transition to a proof-of-stake consensus mechanism, including network upgrades and validator centralization, may add additional uncertainties.
●Bitcoin and Ether Investment Risk: The Fund’s indirect investments in Bitcoin and Ether through holdings in one or more Underlying ETPs expose it to the unique risks of these digital assets. Bitcoin’s price is highly volatile, driven by fluctuating network adoption, acceptance levels, and usage trends. Ether faces similar volatility, compounded by its reliance on decentralized applications (dApps) and smart contract usage, which are subject to innovation cycles and adoption rates. Neither asset operates as legal tender or within central authority systems, exposing them to potential government restrictions. Regulatory actions in various jurisdictions could negatively impact their market values. Both Bitcoin and Ether are susceptible to fraud, theft, market manipulation, and security breaches at trading platforms. Large holders of these assets (”whales”) can influence their prices significantly. Forks in the blockchain networks—such as Ethereum’s earlier split into Ether Classic—can affect demand and performance. Both assets’ prices can be influenced by speculative trading, unrelated to fundamental utility or adoption.
● Digital Assets Risk: Digital Assets like Bitcoin and Ether, designed as mediums of exchange or for utility purposes, are an emerging asset class. Operating independently of any central authority or government backing, they face extreme price volatility and regulatory scrutiny. Trading platforms for Digital Assets remain largely unregulated and prone to fraud and operational failures compared to traditional exchanges. Platform shutdowns, whether due to fraud, technical issues, or security breaches, can significantly impact prices and market stability.
● Digital Asset Markets Risk: The Digital Asset market, particularly for Bitcoin and Ether, has experienced considerable volatility, leading to market disruptions and erosion of confidence among participants. Negative publicity surrounding these disruptions could adversely affect the Fund’s reputation and share trading prices. Ongoing market turbulence could significantly impact the Fund’s value.
● Blockchain Technology Risk: Blockchain technology underpins Bitcoin, Ether, and other digital assets, yet it remains a relatively new and largely untested innovation. Competing platforms, changes in adoption rates, and technological advancements in blockchain infrastructure can affect their functionality and relevance. For Ether, the dependence on its proof-of-stake mechanism and smart contract capabilities introduces risks tied to network performance and scalability. Investments in blockchain-dependent companies or vehicles may experience market volatility and lower trading volumes. Furthermore, regulatory changes, cybersecurity incidents, and intellectual property disputes could undermine the adoption and stability of blockchain technologies.
Recent Market Events Risk. U.S. and international markets have experienced and may continue to experience significant periods of volatility in recent years and months due to a number of economic, political and global macro factors including uncertainty regarding inflation and central banks’ interest rate changes, the possibility of a national or global recession, trade tensions and tariffs, political events, war and geopolitical conflict. These developments, as well as other events, could result in further market volatility and negatively affect financial asset prices, the liquidity of certain securities and the normal operations of securities exchanges and other markets, despite government efforts to address market disruptions.
New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions.
. Lead-Lag Publishing, LLC is not an affiliate of Tidal/Toroso, Tactical Rotation Management, LLC, SYKON Asset Management, Point Bridge Capital, or ACA/Foreside.